NASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $86.43 +1.31 (+1.54%) Closing price 04:00 PM EasternExtended Trading$85.78 -0.65 (-0.75%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About DexCom Stock (NASDAQ:DXCM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DexCom alerts:Sign Up Key Stats Today's Range$85.49▼$86.7850-Day Range$79.84▼$87.5752-Week Range$57.52▼$113.08Volume2.19 million shsAverage Volume4.43 million shsMarket Capitalization$33.89 billionP/E Ratio64.50Dividend YieldN/APrice Target$99.60Consensus RatingModerate Buy Company Overview DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. Read More DexCom Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreDXCM MarketRank™: DexCom scored higher than 94% of companies evaluated by MarketBeat, and ranked 61st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 16 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth21.18% Earnings GrowthEarnings for DexCom are expected to grow by 21.18% in the coming year, from $2.03 to $2.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 64.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.63.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 64.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.05.Price to Earnings Growth RatioDexCom has a PEG Ratio of 1.82. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 16.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.69% of the float of DexCom has been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently increased by 12.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.76 Percentage of Shares Shorted2.69% of the float of DexCom has been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently increased by 12.05%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.63 News SentimentDexCom has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for DexCom this week, compared to 27 articles on an average week.Search Interest13 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.MarketBeat Follows7 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,281,732.00 in company stock.Percentage Held by InsidersOnly 0.32% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address DXCM Stock News HeadlinesDexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern Sells 1,466 SharesJuly 1, 2025 | insidertrades.comTenovi Expands Access to Glucose Data for Remote Patient Monitoring and Cardiometabolic Programs Through Dexcom IntegrationJuly 23 at 7:45 AM | businesswire.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 23 at 2:00 AM | Brownstone Research (Ad)DexCom: Delivering Consistent GrowthJuly 21 at 11:40 AM | seekingalpha.comStill Too Pricey? DexCom's Double-Digit Growth May Not Be EnoughJuly 21 at 10:46 AM | seekingalpha.comDexCom (NASDAQ:DXCM) Rating Increased to Buy at Wall Street ZenJuly 21 at 3:59 AM | americanbankingnews.comWhy This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 YearsJuly 20 at 8:45 AM | fool.comDexCom (NASDAQ:DXCM) Price Target Raised to $100.00July 19, 2025 | americanbankingnews.comSee More Headlines DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $77.77 on January 1st, 2025. Since then, DXCM stock has increased by 11.1% and is now trading at $86.43. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, May, 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.01. The business's revenue for the quarter was up 12.5% on a year-over-year basis. Read the conference call transcript. When did DexCom's stock split? DexCom shares split on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Does DexCom have any subsidiaries? The following companies are subsidiaries of DexCom: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more. Who are DexCom's major shareholders? DexCom's top institutional shareholders include Assenagon Asset Management S.A. (0.31%), Congress Asset Management Co. (0.27%), Chicago Capital LLC (0.23%) and Zevenbergen Capital Investments LLC (0.16%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Jereme M Sylvain, Steven Robert Pacelli, Sadie Stern, Michael Jon Brown, Barry J Regan, Mark G Foletta, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Nicholas Augustinos and Bridgette P Heller. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/01/2025Today7/23/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees10,300Year Founded1999Price Target and Rating Average Price Target for DexCom$99.60 High Price Target$120.00 Low Price Target$85.00 Potential Upside/Downside+15.2%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)$1.34 Trailing P/E Ratio64.50 Forward P/E Ratio42.58 P/E Growth1.82Net Income$576.20 million Net Margins12.90% Pretax Margin17.62% Return on Equity30.05% Return on Assets10.00% Debt Debt-to-Equity Ratio0.55 Current Ratio1.50 Quick Ratio1.32 Sales & Book Value Annual Sales$4.15 billion Price / Sales8.17 Cash Flow$2.28 per share Price / Cash Flow37.87 Book Value$5.38 per share Price / Book16.07Miscellaneous Outstanding Shares392,107,000Free Float390,852,000Market Cap$33.89 billion OptionableOptionable Beta1.44 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:DXCM) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.